epilepsyhere.org.uk Report : Visit Site

Technical data of the epilepsyhere.org.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host epilepsyhere.org.uk. Currently, hosted in Bulgaria and its service provider is GetClouder EOOD .

the related websites

kentnews.co.uk dutyfreedepot.com bluej.org leeds-castle.com gardenfurnitureofdistinction.co.uk thepottedgarden.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

epilepsy here print email g anti epileptic the number of medicines licensed for the treatment of epilepsy has greatly increased in the last twenty years. this does not mean that all patients diagnosed with epilepsy can expect to gain complete control over their seizures with the regular use of prescribed . even the most optimistic prescribers suggest that a success level approaching 70% is the best that can be expected and then after only after various s and dosages have been tried. these anti-epileptic drugs (aeds) are not used to stop seizures whilst they are in progress and they do not cure epilepsy. for information on particular medicines click here it is important that a degree of patience is observed during the search for the best level and type of to control their seizures because as with most medicines the beneficial effects are come at the cost of unwanted side effects. in fact the development of new medicines is linked as much to limiting side effects as providing greater seizure control. different drugs work in different ways, but those for epilepsy all aim to stop seizures happening. before starting them, it is important that your neurologist finds out as much as possible about your epilepsy. this is because the that they prescribe depends on making sure you have epilepsy and finding the type(s) of seizures you have. the will need to be taken regularly and probably over a number of years. your neurologist will take into account any other medical conditions you may have and the for those to make sure there is no contra-indication. s have bothj a proprietary and generic name as explained at the following page before starting you on them, it is important that your neurologist finds out as much as possible about your epilepsy. this is because the that they prescribe depends on making sure you have epilepsy and finding the type(s) of seizures you have. the will need to be taken regularly and often over a number of years. your neurologist will take into account any other medical conditions you may have and the for those to make sure there is no contra-indication which would cause unde sirable side effects. from wednesday 11 january2012, doctors have new advice on the drugs they should prescribe their patients who have epilepsy . this comes as the national institute for health and clinical excellence (nice), the healthcare guidance body, updates the pharmacological recommendations from its clinical guideline on the diagnosis and management of the condition. the guideline has been revised to fully incorporate newer anti-epileptic drugs (aeds) which have emerged in uk clinical practice since the original guidance was published in 2004. carbagen sr (prolonged release carbamazepine) tablets are out of stock in all doses. mylan, the makers of carbagen sr, does not know when it will have these tablets back in stock. standard release carbagen tablets are in stock in 200mg and 400mg doses. if you usually take carbagen sr, speak to your gp, epilepsy nurse or epilepsy specialist for advice. you may need to temporarily switch to a different version of carbamazepine until carbagen sr is back in stock. ema medicine safety committee recommends stronger restrictions on use of sodium valproate in women of childbearing age the new recommendations say that for women with epilepsy, sodium valproate should not be used during pregnancy. however, the recommendations acknowledge that in some women with epilepsy, it may not be possible to stop using the medicine. this is because it may lead to breakthrough or worsened seizures, which can be harmful to the woman and baby. in this situation, the recommendations say women should have appropriate specialist care. in women of a childbearing age, the recommendations say that sodium valproate should not be used unless measures are taken to help the woman avoid becoming pregnant. the prac suggests that a pregnancy prevention programme should be created for this. the pregnancy prevention programme would assess the potential of a woman becoming pregnant, depending on her circumstances. it would suggest pregnancy tests are taken during the treatment as needed. the committee says counselling should be provided about the risks to pregnancy as part of the programme. it also suggests that there should be annual reviews of the treatment. prac recommends that a risk acknowledgement form should be introduced, for people to go through with their doctors at each review. alongside these recommendations, the committee has also said that there should be a visual warning on the medicines’ packaging. they recommend a symbol or a pictogram. a reminder card should also be attached to the packaging to help pharmacists discuss the risks of valproate. the committee is also calling on companies marketing the medicine to provide updated educational materia ls. professor helen cross, clinical advisor to the independent group of experts that developed the guidance on nice's behalf, said: "although many people who have epilepsy are able to have their seizures controlled with , it can take a little time to find the right treatment before a satisfactory outcome can be reached. "the update to the guidance outlines h ow and when doctors should consider treatment for different types of epilepsy, taking into consideration the newer anti-epileptic drugs alongside the more established medicines. we hope that this will enable doctors to continue to provide the best possible care for individuals with epilepsy."ema medicine safety committee recommends stronger restrictions on use of sodium valproate in women of childbearing age the new recommendations say that for women with epilepsy, sodium valproate should not be used during pregnancy. however, the recommendations acknowledge that in some women with epilepsy, it may not be possible to stop using the medicine. this is because it may lead to breakthrough or worsened seizures, which can be harmful to the woman and baby. in this situation, the recommendations say women should have appropriate specialist care. in women of a childbearing age, the recommendations say that sodium valproate should not be used unless measures are taken to help the woman avoid becoming pregnant. the prac suggests that a pregnancy prevention programme should be created for this. the pregnancy prevention programme would assess the potential of a woman becoming pregnant, depending on her circumstances. it would suggest pregnancy tests are taken during the treatment as needed. the committee says counselling should be provided about the risks to pregnancy as part of the programme. it also suggests that there should be annual reviews of the treatment. prac recommends that a risk acknowledgement form should be introduced, for people to go through with their doctors at each review. alongside these recommendations, the committee has also said that there should be a visual warning on the medicines’ packaging. they recommend a symbol or a pictogram. a reminder card should also be attached to the packaging to help pharmacists discuss the risks of valproate. the committee is also calling on companies marketing the medicine to provide updated educational materials. march meet ask for repeat prescriptions in plenty of time! people with epilepsy are being urged not to leave it to the last minute to get their prescriptions for anti-epileptic drugs (aeds) dispensed. the national society for epilepsy inform that recent press reports have highlighted shortages in supply of some drugs to uk patients which, it is claimed, are being sold overseas for higher prices.they (nse) are urging patients to present their prescription to their pharmacist well before they run out of their .nse’s chief pharmacist janet clark said: “there have been problems with the supply of some aeds for a little while. pharmacists are aware that there are alternative ways of obtaining the drugs to ensure continuity of supply but this can take an extra day or so. i would urge patients not

URL analysis for epilepsyhere.org.uk

http://www.epilepsyhere.org.uk//#top
http://www.epilepsyhere.org.uk///index.php
http://www.epilepsyhere.org.uk///index.php/coming-events
http://www.epilepsyhere.org.uk///index.php/information-on-epilepsy
http://www.epilepsyhere.org.uk///index.php/home
http://www.epilepsyhere.org.uk///index.php?tmpl=component&print=1
http://www.epilepsyhere.org.uk///index.php/current-news
http://www.epilepsyhere.org.uk///index.php/what-we-do
http://www.epilepsyhere.org.uk///index.php/contact-us
http://www.epilepsyhere.org.uk///index.php/help
http://www.epilepsyhere.org.uk///index.php/useful-first-aid-hints
http://www.epilepsyhere.org.uk///index.php/epilepsy-what-it-does
http://www.epilepsyhere.org.uk///index.php/medication/generic-and-branded-medication
http://www.epilepsyhere.org.uk///index.php/component/mailto/?tmpl=component&template=protostar&link=10b1fc1ea665a95b62f3e27aa9a62badcf90c44b
http://www.epilepsyhere.org.uk///index.php/equaulity-act-2010
nice.org.uk
cse.google.co.uk
epilepsysociety.org.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain name:
epilepsyhere.org.uk

Registrant:
Epilepsy HERE

Registrant type:
UK Registered Charity, (Charity number: 1079172)

Registrant's address:
11 Beaumanor
Herne Bay
Kent
CT6 5TQ
United Kingdom

Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 26-Apr-2016

Registrar:
TUCOWS Inc t/a TUCOWS [Tag = TUCOWS-CA]
URL: http://www.tucowsdomains.com

Relevant dates:
Registered on: 06-Jul-2001
Expiry date: 06-Jul-2018
Last updated: 21-Jun-2016

Registration status:
Registered until expiry date.

Name servers:
ns1.uk14.siteground.eu
ns2.uk14.siteground.eu

WHOIS lookup made at 07:02:28 09-Aug-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER uk.whois-servers.net

  ARGS epilepsyhere.org.uk

  PORT 43

  TYPE domain

OWNER

  ORGANIZATION Epilepsy HERE

TYPE
UK Registered Charity, (Charity number: 1079172)

ADDRESS
11 Beaumanor
Herne Bay
Kent
CT6 5TQ
United Kingdom
Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 26-Apr-2016

DOMAIN

  SPONSOR TUCOWS Inc t/a TUCOWS [Tag = TUCOWS-CA]

  CREATED 2001-07-06

  CHANGED 2016-06-21

STATUS
Registered until expiry date.

NSERVER

  NS1.UK14.SITEGROUND.EU 185.123.97.178

  NS2.UK14.SITEGROUND.EU 77.104.128.189

  NAME epilepsyhere.org.uk

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .